alexa A Review of Fatty Liver/NASH and Liver Cirrhosis: Genetics, Prevention, Nutritional, Behavioral Modification, Exercise, Pharmaceutical, Biophysics and Biotech Therapy

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

A Review of Fatty Liver/NASH and Liver Cirrhosis: Genetics, Prevention, Nutritional, Behavioral Modification, Exercise, Pharmaceutical, Biophysics and Biotech Therapy

This article reviews the current factors concerning obesity, metabolic syndrome or DM2 and the accumulation of fat which can result in fatty liver or steatohepatitis (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) and cirrhosis. The pathophysiology is discussed as well as the current treatment and nutritional options of betaine, SAMe, phosphatidylcholine, silymarin with vitamin E and probiotics. Since obesity, metabolic syndrome and NAFLD/NASH are polygenic as well as epigenetic, the current nutritional, pharmaceutical and biotec solutions are fairly limited. Future options may include biophysical such as temperature control, light therapy ormelatonin and moderate magnetic field therapy capable of regulating over 2500 genes as well as novel can nabinoidagents and polyphenols.

Citation: Nichols TW (2013) A Review of Fatty Liver/NASH and Liver Cirrhosis: Genetics, Prevention, Nutritional, Behavioral Modification, Exercise, Pharmaceutical, Biophysics and Biotech Therapy. J Liver 3: 144. doi: 10.4172/2167-0889.1000144

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords